Neurosense Therapeutics

NRSN · NASDAQ

$2.39−$0.275 (−10.32%)TodayMarket closed · Oct 20, 7:56 PM ET

Prev close $2.67

About NRSN

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Employees: 16
Headquarters: Herzliya
Listed: Dec 9, 2021
Sector: Health Care
Industry: Biotechnology
Website: neurosense-tx.com

Leadership

Neurosense Therapeutics executives
Name	Title	Since	Age
Mark Leuchtenberger	—	—	—
Alon Ben-Noon	—	2017	42
Or Eisenberg	—	—	40
Ferenc Tracik	—	—	58
Cary Claiborne	—	—	61
Caren Deardorf	—	—	58
Revital Mandil-Levin	—	—	47
Christine Pellizzari	—	—	55

Similar companies

Companies in the same industry as Neurosense Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.